Venturi Wealth Management LLC Has $12.61 Million Holdings in Amgen, Inc. (NASDAQ:AMGN)

Venturi Wealth Management LLC cut its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 52,286 shares of the medical research company’s stock after selling 857 shares during the quarter. Amgen accounts for about 1.5% of Venturi Wealth Management LLC’s investment portfolio, making the stock its 12th largest holding. Venturi Wealth Management LLC’s holdings in Amgen were worth $12,605,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in AMGN. Tibra Equities Europe Ltd raised its stake in shares of Amgen by 62.8% during the 3rd quarter. Tibra Equities Europe Ltd now owns 19,700 shares of the medical research company’s stock worth $3,812,000 after purchasing an additional 7,600 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in shares of Amgen by 0.7% during the 3rd quarter. Daiwa Securities Group Inc. now owns 38,048 shares of the medical research company’s stock worth $7,362,000 after purchasing an additional 258 shares in the last quarter. Lowe Brockenbrough & Co. Inc. raised its stake in shares of Amgen by 0.5% during the 3rd quarter. Lowe Brockenbrough & Co. Inc. now owns 30,380 shares of the medical research company’s stock worth $5,879,000 after purchasing an additional 155 shares in the last quarter. First Merchants Corp raised its stake in shares of Amgen by 10.1% during the 3rd quarter. First Merchants Corp now owns 24,777 shares of the medical research company’s stock worth $4,795,000 after purchasing an additional 2,265 shares in the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its stake in shares of Amgen by 0.6% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 199,207 shares of the medical research company’s stock worth $36,710,000 after purchasing an additional 1,124 shares in the last quarter. Hedge funds and other institutional investors own 76.69% of the company’s stock.

Shares of AMGN stock traded down $1.79 during trading on Monday, reaching $223.80. The company had a trading volume of 319,986 shares, compared to its average volume of 1,948,167. The firm’s 50 day simple moving average is $239.01 and its two-hundred day simple moving average is $211.14. The company has a debt-to-equity ratio of 2.54, a current ratio of 2.89 and a quick ratio of 2.59. Amgen, Inc. has a one year low of $166.30 and a one year high of $244.99. The company has a market capitalization of $134.04 billion, a PE ratio of 17.18, a PEG ratio of 1.95 and a beta of 1.11.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, October 29th. The medical research company reported $3.66 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.53 by $0.13. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The firm’s revenue was down 2.8% compared to the same quarter last year. During the same period last year, the business earned $3.69 EPS. Analysts forecast that Amgen, Inc. will post 14.64 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 14th will be given a $1.60 dividend. This is an increase from Amgen’s previous quarterly dividend of $1.45. This represents a $6.40 annualized dividend and a yield of 2.86%. The ex-dividend date of this dividend is Thursday, February 13th. Amgen’s payout ratio is currently 40.28%.

A number of research firms have recently weighed in on AMGN. Bank of America began coverage on Amgen in a research note on Wednesday, October 16th. They set a “neutral” rating and a $215.00 price target for the company. Leerink Swann raised their price target on Amgen from $189.00 to $205.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. BMO Capital Markets raised their price target on Amgen from $240.00 to $275.00 and gave the stock an “outperform” rating in a research note on Thursday, January 9th. UBS Group raised their price target on Amgen from $194.00 to $238.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 22nd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $255.00 price target on shares of Amgen in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the stock. Amgen presently has an average rating of “Hold” and an average target price of $240.11.

In other Amgen news, EVP Jonathan P. Graham sold 9,000 shares of Amgen stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $230.54, for a total value of $2,074,860.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total value of $91,566.25. Following the completion of the transaction, the director now directly owns 5,413 shares in the company, valued at $1,166,230.85. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,162 shares of company stock worth $4,214,030. Company insiders own 0.25% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: Cost of Debt

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.